| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Giorgio Gentile | Q37831261 |
| Gianpaolo Reboldi | Q37831266 | ||
| P2093 | author name string | Fabio Angeli | |
| Paolo Verdecchia | |||
| P2860 | cites work | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
| Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective | Q28196527 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias | Q29616292 | ||
| Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 | ||
| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group | Q29619460 | ||
| Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. | Q30307744 | ||
| An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. | Q30349890 | ||
| Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy | Q30837772 | ||
| Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care | Q31136915 | ||
| Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study | Q33395540 | ||
| The devil is in the detail - a multifactorial intervention to reduce blood pressure in co-existing diabetes and chronic kidney disease: a single blind, randomized controlled trial | Q33523202 | ||
| Standards of medical care in diabetes--2010. | Q33554238 | ||
| Diuretic complications | Q33827337 | ||
| Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study | Q33945028 | ||
| Effects of intensive blood-pressure control in type 2 diabetes mellitus | Q34008161 | ||
| Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease | Q34432935 | ||
| Thiazide diuretics, potassium, and the development of diabetes: a quantitative review | Q34542023 | ||
| Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial | Q34571157 | ||
| Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease | Q35159242 | ||
| Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia | Q35594111 | ||
| The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease | Q36101353 | ||
| Antihypertensive agents for primary prevention of diabetic nephropathy | Q36246236 | ||
| The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease | Q36335340 | ||
| Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis | Q36336393 | ||
| Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history | Q36659512 | ||
| Early stopping of randomized clinical trials for overt efficacy is problematic | Q37069734 | ||
| Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 | ||
| Lowering blood pressure reduces renal events in type 2 diabetes | Q37146445 | ||
| The effect of a hypertension self-management intervention on diabetes and cholesterol control | Q37154655 | ||
| Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials | Q37202153 | ||
| Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus | Q37629831 | ||
| Cardiovascular events during differing hypertension therapies in patients with diabetes | Q39858492 | ||
| ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. | Q40705963 | ||
| Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus | Q42661482 | ||
| Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity | Q42829351 | ||
| Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. | Q43112581 | ||
| Composite renal endpoints: was ACCOMPLISH accomplished? | Q43156208 | ||
| Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial | Q43156210 | ||
| Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension | Q43274969 | ||
| Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study | Q43843866 | ||
| Diabetes and diabetic nephropathy - a worldwide problem | Q44083396 | ||
| Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control | Q44439812 | ||
| Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study | Q45069632 | ||
| Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. | Q45145783 | ||
| Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. | Q46002601 | ||
| Renal protective effect of enalapril in diabetic nephropathy | Q46080832 | ||
| Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH | Q46455413 | ||
| Medical clinics versus usual care for patients with both diabetes and hypertension: a randomized trial | Q46501552 | ||
| Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients | Q46531703 | ||
| Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study | Q46620351 | ||
| Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus | Q46687663 | ||
| Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study | Q46691578 | ||
| Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients | Q46725325 | ||
| Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. | Q51562539 | ||
| Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. | Q51574871 | ||
| Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | Q56970676 | ||
| 2007 Guidelines for the Management of Arterial Hypertension | Q56970780 | ||
| Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial | Q57274347 | ||
| ACE-inhibitor use and the long-term risk of renal failure in diabetes | Q57446641 | ||
| Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials | Q57551572 | ||
| When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal | Q61456541 | ||
| Renoprotection by blocking the RAAS in diabetic nephropathy—fact or fiction? | Q61948392 | ||
| Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis | Q64459160 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes | Q73909414 | ||
| Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus | Q77985744 | ||
| Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis | Q79969450 | ||
| Beta-adrenergic blocking agents in patients with diabetes-- friend and foe | Q80336737 | ||
| Treatment of hypertension in patients with diabetes | Q80794912 | ||
| Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials | Q81897757 | ||
| Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD? | Q83232765 | ||
| The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease | Q83265037 | ||
| ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk? | Q83462152 | ||
| [Nephrosclerosis. The Cinderella of chronic kidney disease] | Q84334092 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 176-185 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Current Atherosclerosis Reports | Q20821076 |
| P1476 | title | Optimal therapy in hypertensive subjects with diabetes mellitus | |
| P478 | volume | 13 |
| Q52639492 | Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study. |
| Q36156587 | Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes |
| Q26824870 | Epidemiology and prevention of stroke: a worldwide perspective |
| Q33706621 | Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus |
| Q38068591 | Intensive blood pressure control in obese diabetic patients: clinical relevance of stroke prevention in the ACCORD trial |
| Q38265818 | Novel effective drugs for diabetic kidney disease? or not? |
| Q37964515 | Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes |
Search more.